Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: Comparison with fluorescence in situ hybridization (FISH)

Diagnostic Molecular Pathology

Volumn 17, Issue 4, 2008, Pages 227-230

  Fischer, Ingeborg ^a,c   De La Cruz, Clarissa ^b   Rivera, Andreana L ^b   Aldape, Kenneth ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Division of Neuropathology   (United States)

Author keywords

Chromogenic in situ hybridization; EGFR; Glioblastoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GLIOBLASTOMA; GOLD STANDARD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY;

GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PATHOLOGY, SURGICAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 57649138665     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181642230     Document Type: Article

References (20)

1. Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Nervous System. Lyon: IARC Press; 2000.
2. Ohgaki H, Schauble B, zur Hausen A, et al. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch. 1995;427:113-118.
3. Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys. 2004;58:927-931.
4. Leuraud P, Taillandier L, Medioni J, et al. Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res. 2004;64:4648-4653.
5. Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol. 2006;19:481-487.
6. Sholl LM, John Iafrate A, Chou YP, et al. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol. 2007;20:1028-1035.
7. Jarvela S, Helin H, Haapasalo J, et al. Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol Appl Neurobiol. 2006;32:441-450.
8. Quezado M, Ronchetti R, Rapkiewicz A, et al. Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM. Clin Neuropathol. 2005;24:163-169.
9. Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006;12:3935-3941.
10. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246-1256.
11. Fuller CE, Schmidt RE, Roth KA, et al. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol. 2003;62:1118-1128.
12. Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther. 2007;6:1167-1174.
13. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol. 2005;18:1015-1021.
14. Marquez A, Wu R, Zhao J, et al. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol. 2004;13:1-8.
15. Daniele L, Macri L, Schena M, et al. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther. 2007;6:1223-1229.
16. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-1453.
17. Layfield LJ, Willmore C, Tripp S, et al. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol. 2006;14:91-96.
18. Tohma Y, Gratas C, Biernat W, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol. 1998;57:684-689.
19. Tripp SR, Willmore-Payne C, Layfield LJ. Relationship between EGFR overexpression and gene amplification status in central nervous system gliomas. Anal Quant Cytol Histol. 2005;27:71-78.
20. Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol. 2004;35:647-653.